Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”
-
Published:2024
Issue:
Volume:40
Page:100806
-
ISSN:2468-2942
-
Container-title:Cancer Treatment and Research Communications
-
language:en
-
Short-container-title:Cancer Treatment and Research Communications
Author:
Patra Pritish ChandraORCID
Reference10 articles.
1. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP;Bonadonna;Cancer,1975
2. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma;Engert;N. Engl. J. Med.,2010
3. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's Lymphoma: final analysis of the German Hodgkin Study Group HD11 trial;Eich;J. Clin. Oncol.,2010
4. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N. Engl. J. Med.,1992
5. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's Lymphoma;Johnson;N. Engl. J. Med.,2016